Heat Biologics, Inc. Presents Proprietary Allogeneic Cell Line Antigen Screening Algorithm and Systematic Analysis of Combination Tumor Immunotherapy Preclinical Data at the 105th Annual Meeting of the American Association for Cancer Research - Seite 2

"The results of the combination immunotherapy study indicate that specific combinations of vaccination, checkpoint inhibition and T cell costimulation are preferred over other combinations as well as over monotherapy with any single agent," said Dr. Schreiber. "Over 30 combinations are possible with checkpoint inhibitors and T cell costimulators already in clinical development. This comparative data will enable Heat to select the most efficacious combination therapy to bring forward into patients in subsequent clinical trials."

About Heat Biologics, Inc.
Heat Biologics, Inc. is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT therapeutic vaccines to combat a wide range of cancers. Our ImPACT Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat will be entering Phase 2 trials with its HS-110 against non-small cell lung cancer and is conducting Phase 1/2 clinical trials with its HS-410 against bladder cancer. For more information, please visit www.heatbio.com.

Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the potential for Heat's ImPACT Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT Therapy to perform as designed and Heat's ability to achieve its development and commercialization strategies. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Heat Biologics, Inc. Contact Information:

Matthew Czajkowski
Chief Financial Officer
[phone]
Email Contact

Jenene Thomas
Investor Relations Advisor
Jenene Thomas Communications, LLC
[phone]
Email Contact